Pharmacological Effects of Novel Peptide Drugs on Allergic Rhinitis at the Small Ribonucleic Acids Level.

Li-Feng An,Jian Yu,Lin Li,Hao Li,Zhan-Dong Li

doi:10.3389/fgene.2020.560812

Li-Feng An, Jian Yu + Show 3 more

Open Access

https://doi.org/10.3389/fgene.2020.560812

Copy DOI

Abstract

Using an allergic rhinitis (AR) model, we evaluated the pharmacological effects of novel peptide drugs (P-ONE and P-TWO) at the small RNA (sRNA) level. Using high-throughput sequencing, we assessed the sRNA expression profile of the negative control, AR antagonist (positive control), P-ONE, and P-TWO groups. By functional clustering and Gene Ontology and KEGG pathway analyses, we found that sRNA target genes have a specific enrichment pattern and may contribute to the effects of the novel peptides. Small RNA sequencing confirmed the biological foundations of novel and traditional AR treatments and suggested unique pharmacological effects. Our findings will facilitate evaluation of the pathogenesis of AR and of the pharmacological mechanisms of novel peptide drugs.

Highlights

Allergic rhinitis (AR) (Maoz-Segal et al, 2019) is defined as inflammation of the nasal mucosa induced by an allergic reaction; it is known as anaphylaxis (Turner et al, 2019)
We sequenced the microRNAs from four group: model establishment group; models adding antagonists against histamine receptor 4 (HR4); group P-ONE for models adding peptide P-ONE and group P-TWO for models adding peptide P-TWO
Discussion on Functional Clustering of Genes Targeted by the Differential Expressed MicroRNAs. Apart from such phenotypic discussion on the expression comparison of small RNAs in different groups, using gene ontology and KEGG annotation and clustering, we identified some specific enrichment patterns under different therapeutic conditions, helping reveal the potential pharmacological effects of P-ONE and P-TWO comparing to traditional HR4 antagonists

Summary

Introduction

Allergic rhinitis (AR) (Maoz-Segal et al, 2019) is defined as inflammation of the nasal mucosa induced by an allergic reaction; it is known as anaphylaxis (allergy) (Turner et al, 2019). Based on the clinical symptoms, AR can be classified into four groups based on its persistence and severity (Settipane and Charnock, 2016; Jung et al, 2020). AR of > 4-week duration is classified as persistent and AR with only mild symptoms as mild. These classifications can be combined; for instance, mild persistent AR (Settipane and Charnock, 2016). AR is an important threat to human health globally

Methods

Results

Discussion

Conclusion